The Effects of Contact Lenses With UV/HEV-Filter on Visual Function

Sponsor
Johnson & Johnson Vision Care, Inc. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05601544
Collaborator
(none)
167
1
6
3.1
53.5

Study Details

Study Description

Brief Summary

This is a 2-phase, single-site, non-dispensing, randomized, controlled, double-masked, 2x2 crossover study to objectively measure potential benefits of a new UV/HEV filter using psychophysical testing techniques.

Condition or Disease Intervention/Treatment Phase
  • Device: ACUVUE OASYS 1-Day
  • Device: ACUVUE OASYS MAX 1-Day
  • Device: ACUVUE OASYS Multifocal
  • Device: ACUVUE OASYS MAX 1-Day Multifocal
  • Device: ACUVUE OASYS 1-Day for Astigmatism
  • Device: senofilcon A based contact lens (toric) with new UV/HEV filter
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
167 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
The Effects of Contact Lenses With UV/HEV-Filter on Visual Function
Actual Study Start Date :
Dec 9, 2022
Anticipated Primary Completion Date :
Mar 14, 2023
Anticipated Study Completion Date :
Mar 14, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Sphere TEST/CONTROL

Eligible subjects who are habitual wearers of soft contact lenses that receive the sphere lenses will be randomized into the sphere TEST/CONTROL sequence.

Device: ACUVUE OASYS 1-Day
Sphere CONTROL

Device: ACUVUE OASYS MAX 1-Day
Sphere TEST

Experimental: Sphere CONTROL/TEST

Eligible subjects who are habitual wearers of soft contact lenses that receive the sphere lenses will be randomized into the sphere CONTROL/TEST sequence.

Device: ACUVUE OASYS 1-Day
Sphere CONTROL

Device: ACUVUE OASYS MAX 1-Day
Sphere TEST

Experimental: Multifocal TEST/CONTROL

Eligible subjects who are habitual wearers of soft contact lenses that receive the multifocal lenses will be randomized into the multifocal TEST/CONTROL sequence.

Device: ACUVUE OASYS Multifocal
Multifocal CONTROL

Device: ACUVUE OASYS MAX 1-Day Multifocal
Multifocal TEST

Experimental: Multifocal CONTROL/TEST

Eligible subjects who are habitual wearers of soft contact lenses that receive the multifocal lenses will be randomized into the multifocal CONTROL/TEST sequence.

Device: ACUVUE OASYS Multifocal
Multifocal CONTROL

Device: ACUVUE OASYS MAX 1-Day Multifocal
Multifocal TEST

Experimental: Toric TEST/CONTROL

Eligible subjects who are habitual wearers of soft contact lenses that receive the toric lenses will be randomized into the toric TEST/CONTROL sequence.

Device: ACUVUE OASYS 1-Day for Astigmatism
Toric CONTROL

Device: senofilcon A based contact lens (toric) with new UV/HEV filter
Toric TEST

Experimental: Toric CONTROL/TEST

Eligible subjects who are habitual wearers of soft contact lenses that receive the toric lenses will be randomized into the toric CONTROL/TEST sequence.

Device: ACUVUE OASYS 1-Day for Astigmatism
Toric CONTROL

Device: senofilcon A based contact lens (toric) with new UV/HEV filter
Toric TEST

Outcome Measures

Primary Outcome Measures

  1. Visual Range [up to 2-week follow-up]

    Visual range will be tested binocularly at 8 cycles per degree in units of log relative energy (LRE) between 0.00-10.00. Visual range is defined as the log relative energy of simulated haze needed to obscure an otherwise high contrast grating target.

Secondary Outcome Measures

  1. Motion Detection [up to 2-week follow-up]

    Motion detection will be tested binocularly in units of mm between 0.00-10.00. Motion detection is defined as the distance needed (in mm) to determine that a test light has moved from a standard position.

  2. Brightness Perception [up to 2-week follow-up]

    Brightness perception will be tested binocularly in units of log relative energy (LRE) between 0.00-700.00. Brightness perception is defined as the log relative energy needed to match a standard stimulus to a natural scene, across 10 different projected scenes.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
Potential subjects must satisfy all of the following criteria to be enrolled in the study:
The subject must:
  1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.

  2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.

  3. Be between 18 and 70 (inclusive) years of age at the time of screening.

  4. By self-report, habitually wear soft contact lenses (sphere, multifocal, toric) in both eyes in a daily reusable or daily disposable wear modality (i.e. not extended wear modality). Habitual wear is defined as a minimum of 6 hours of wear per day, for a minimum of 5 days per week during the past 30 days.

  5. If applicable, those subjects receiving the spherical lenses will need a vertex-corrected distance refraction within the range of -1.00 through -6.00 DS

  6. If applicable, those subjects receiving the multifocal lenses will need a vertex-corrected distance refraction within the range of -1.00 through -6.00 DS

  7. If applicable, those subjects receiving the toric lenses will need a vertex-corrected distance refraction within the range of -1.50 through -4.00 DS, -0.625 through -1.625 DC, and cylinder axes: 80/90/100, 170/180/10

  8. The best corrected, monocular, distance visual acuity must be 20/25 or better in each eye

Exclusion Criteria:

Potential subjects who meet any of the following criteria will be excluded from participating in the study:

The subject must not:
  1. Be currently pregnant or lactating.

  2. Be currently using any ocular medications or have any ocular infection of any type.

  3. By self-report, have any ocular or systemic disease, allergies, infection, or use of medication that the investigator believes might contraindicate or interfere with contact lens wear, or otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus [HIV]), autoimmune disease (e.g. rheumatoid arthritis, Sjögren's syndrome), or history of serious mental illness or seizures. See section 9.1 for additional details regarding excluded systemic medications.

  4. Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, SoftPerm) within the past 6 months.

  5. Be currently wearing lenses in an extended wear modality.

  6. Have participated in a contact lens or lens care product clinical trial within 14 days prior to study enrollment.

  7. Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse) of the clinical site.

  8. (Phase 2 only): Have participated in Phase 1 of the study.

  9. Have clinically significant (grade 3 or higher on the FDA grading scale) slit lamp findings (e.g., corneal edema, neovascularization or staining, tarsal abnormalities or bulbar injection) or other corneal or ocular disease or abnormalities that the investigator believes might contraindicate contact lens wear or may otherwise compromise study endpoints (including entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, moderate or above corneal distortion, herpetic keratitis).

  10. Have a history of strabismus or amblyopia.

  11. Have fluctuations in vision due to clinically significant dry eye or other ocular conditions.

  12. Have had or have planned (within the study period) any ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, iridotomy, retinal laser photocoagulation, etc.).

Contacts and Locations

Locations

Site City State Country Postal Code
1 The University of Georgia Athens Georgia United States 30602

Sponsors and Collaborators

  • Johnson & Johnson Vision Care, Inc.

Investigators

  • Study Director: Johnson & Johnson Vision Care, Inc. Clinical Trial, Johnson & Johnson Vision Care, Inc.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Johnson & Johnson Vision Care, Inc.
ClinicalTrials.gov Identifier:
NCT05601544
Other Study ID Numbers:
  • CR-6480
First Posted:
Nov 1, 2022
Last Update Posted:
Jan 25, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes

Study Results

No Results Posted as of Jan 25, 2023